Glenview Capital Management Lifted Its Hca Holdings (HCA) Stake, Juno Therapeutics (JUNO) Shorts Increased By 10.48%

July 14, 2017 - By Migdalia James

Juno Therapeutics Incorporated (NASDAQ:JUNO) had an increase of 10.48% in short interest. JUNO’s SI was 18.18 million shares in July as released by FINRA. Its up 10.48% from 16.45M shares previously. With 2.58M avg volume, 7 days are for Juno Therapeutics Incorporated (NASDAQ:JUNO)’s short sellers to cover JUNO’s short positions. The SI to Juno Therapeutics Incorporated’s float is 29.96%. About 2.10 million shares traded. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since July 14, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.

Glenview Capital Management Llc increased Hca Holdings Inc (HCA) stake by 13.71% reported in 2016Q4 SEC filing. Glenview Capital Management Llc acquired 2.19M shares as Hca Holdings Inc (HCA)’s stock declined 2.93%. The Glenview Capital Management Llc holds 18.18M shares with $1.35 billion value, up from 15.99 million last quarter. Hca Holdings Inc now has $31.83 billion valuation. The stock rose 0.07% or $0.06 reaching $86.63 per share. About 702,993 shares traded. HCA Healthcare Inc (NYSE:HCA) has risen 7.08% since July 14, 2016 and is uptrending. It has underperformed by 9.62% the S&P500.

Among 14 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 have Buy rating, 1 Sell and 7 Hold. Therefore 43% are positive. Juno Therapeutics Inc had 28 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Buy” rating given on Friday, January 29 by Suntrust Robinson. Standpoint Research initiated the shares of JUNO in report on Monday, August 24 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. Standpoint Research downgraded the stock to “Hold” rating in Thursday, October 29 report. The firm earned “Buy” rating on Tuesday, December 15 by Standpoint Research. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by Leerink Swann on Monday, November 28. As per Thursday, February 2, the company rating was initiated by Wedbush. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Sell” rating by BTIG Research on Thursday, June 8. The firm has “Buy” rating given on Friday, August 5 by Maxim Group. The firm has “Neutral” rating given on Friday, July 8 by JP Morgan.

Juno Therapeutics, Inc. is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The company has market cap of $2.90 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

Investors sentiment decreased to 1.04 in 2016 Q4. Its down 0.36, from 1.4 in 2016Q3. It worsened, as 33 investors sold Juno Therapeutics Inc shares while 37 reduced holdings. 23 funds opened positions while 50 raised stakes. 45.31 million shares or 3.22% more from 43.89 million shares in 2016Q3 were reported. Washington Tru Bancshares invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). First Trust Advisors Limited Partnership accumulated 0.05% or 936,683 shares. 35,876 were accumulated by Wells Fargo And Mn. Citadel Ltd Liability Company holds 43,019 shares or 0% of its portfolio. Northern Tru reported 281,837 shares stake. Glob X Management Company Llc holds 0% or 239 shares in its portfolio. State Street invested 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO). Proshare Advsrs Ltd reported 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO). Prelude Capital Mngmt Limited Company reported 5,044 shares. California Employees Retirement System holds 0% or 74,300 shares. Alps owns 0.01% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 101,741 shares. 116,200 were reported by Clearline Limited Partnership. Swiss Bancorp invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Morgan Stanley invested in 0.01% or 961,187 shares. Td Asset Mgmt holds 0% or 35,200 shares in its portfolio.

Since January 17, 2017, it had 2 insider buys, and 26 selling transactions for $23.97 million activity. Englebright Jane D. had sold 5,005 shares worth $426,993 on Monday, May 8. Another trade for 54,689 shares valued at $4.50 million was made by Davis Jana Joustra on Tuesday, May 23. FRIST THOMAS F JR had bought 361,205 shares worth $30.00M. STEELE JOHN M also sold $2.60 million worth of HCA Healthcare Inc (NYSE:HCA) on Tuesday, February 7. $142,148 worth of HCA Healthcare Inc (NYSE:HCA) shares were sold by Torres Kathryn A.. The insider Cuffe Michael S. sold $181,718. FRIST PATRICIA C had bought 361,205 shares worth $30.00 million.

Glenview Capital Management Llc decreased Hertz Global Hldgs Inc stake by 2.24M shares to 4.36 million valued at $94.11M in 2016Q4. It also reduced Phh Corp (NYSE:PHH) stake by 178,132 shares and now owns 4.54 million shares. Asbury Automotive Group Inc (NYSE:ABG) was reduced too.

Among 23 analysts covering HCA Holdings (NYSE:HCA), 15 have Buy rating, 0 Sell and 8 Hold. Therefore 65% are positive. HCA Holdings had 50 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, June 1. The stock of HCA Healthcare Inc (NYSE:HCA) has “Buy” rating given on Thursday, October 22 by Mizuho. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, January 29. The firm has “Market Perform” rating given on Thursday, June 16 by Bernstein. Mizuho downgraded the shares of HCA in report on Wednesday, November 9 to “Neutral” rating. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, October 28. KeyBanc Capital Markets upgraded the stock to “Overweight” rating in Thursday, October 13 report. The stock has “Neutral” rating by Goldman Sachs on Thursday, December 17. The firm has “Outperform” rating given on Wednesday, June 7 by Leerink Swann. The firm has “Overweight” rating by Piper Jaffray given on Wednesday, January 4.

Investors sentiment increased to 0.79 in Q4 2016. Its up 0.12, from 0.67 in 2016Q3. It improved, as 69 investors sold HCA shares while 219 reduced holdings. 60 funds opened positions while 167 raised stakes. 263.84 million shares or 1.88% more from 258.96 million shares in 2016Q3 were reported. Wedge Capital L LP Nc holds 0.11% or 152,514 shares in its portfolio. The New York-based Chieftain Inc has invested 7.06% in HCA Healthcare Inc (NYSE:HCA). Goldman Sachs Gp Incorporated accumulated 0.02% or 1.19M shares. Arrowgrass Capital Partners (Us) Ltd Partnership has 0.04% invested in HCA Healthcare Inc (NYSE:HCA) for 44,225 shares. Intact Invest holds 0.01% or 5,100 shares. Exchange Capital Management Inc holds 72,176 shares. The Massachusetts-based Baystate Wealth Management Limited Liability Corp has invested 0% in HCA Healthcare Inc (NYSE:HCA). Smith Asset Gp LP owns 188,850 shares or 0.41% of their US portfolio. Narwhal Mngmt owns 41,105 shares. Glenview Capital Lc invested in 9.1% or 18.18 million shares. State Teachers Retirement System accumulated 0.1% or 513,431 shares. House Ltd Llc accumulated 0.37% or 33,075 shares. Retail Bank Of Montreal Can holds 0.05% or 713,892 shares. Acadian Asset Mngmt Lc, a Massachusetts-based fund reported 3,437 shares. Stephens Ar accumulated 20,341 shares or 0.06% of the stock.